Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.67 |
| ▸ | ITGB6 | P18564 | 17/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.67 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.67 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.67 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.67 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276613 | 1.00 | ITGAV (0.67) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL327994 | 0.99 | ITGAV (0.68) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL5584546 | 0.97 | ITGAV (0.69) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL328013 | 0.93 | ITGAV (0.66) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL277016 | 0.92 | ITGAV (0.59) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL328048 | 0.92 | ITGAV (0.60) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL21744205 | 0.91 | ITGAV (0.69) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL21744207 | 0.91 | ITGAV (0.69) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL13039582 | 0.91 | ITGAV (0.59) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| Hydrochloric Acid SCHEMBL21713035 | 0.91 | ITGAV (0.69) | ITGAVITGB6ITGB3ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189174-A1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR INHIBITING PROGRESSION OF, PATHOGENIC OCULAR NEOVASCULARIZATION | WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.) | 2011-08-04 | — | — | US | disclosed |
| WO-2011094285-A1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR INHIBITING PROGRESSION OF, PATHOGENIC OCULAR NEOVASCULARIZATION | BAUSCH & LOMB INCORPORATED (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189174-A1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR INHIBITING PROGRESSION OF, PATHOGENIC OCULAR NEOVASCULARIZATION | ITGB2, ITGB1, ITGAV | ITGAV 3/4885ITGB6 14/4885ITGB3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.